Vertama raises seven-figure seed funding for efficient, digital healthcare processes

July 12, 2023

Berlin, 12 July 2023 – Vertama digitises medical reporting processes in the hospital environment, transforming time-consuming manual work into efficient, partially fully automated processes. Led by High-Tech Gründerfonds (HTGF), Berlin Angel Fund and renowned business angels are jointly investing in the seed round of the Berlin-based start-up.

Following the philosophy of developing accessible services that can be easily implemented in existing systems as scalable products, Vertama has already convinced more than 50 hospitals in Germany.

In particular, the legal requirement for digital reporting to the German Electronic Reporting and Information System for Infection Prevention (DEMIS) in autumn 2022 has led to a significant additional workload for hospitals, which Vertama’s ELIM (Electronic Infection Prevention Reporting) and BELIM (Electronic Bed Occupancy Reporting) services handle as far as possible automatically.

The notifications required by the Infection Protection Act can be carried out efficiently and conveniently using ELIM and BELIM. For us, however, this is just a starting point, as many processes in the communication between hospitals and authorities such as the RKI are still in need of digitalisation and automation.

Andre Sturm, CEO of Vertama

Once implemented, the bed occupancy report (BELIM) is completely autonomous. The figures are automatically determined from the hospital’s SAP system at the desired time and sent directly to the Robert-Koch Institute’s FHIR interface, DEMIS. In this synchronous process, DEMIS immediately returns a transmission confirmation, which is automatically saved in the hospital’s archive system.

The required reports on infections and hospitalisations (ELIM) also take full advantage of the IT structure. The relevant forms are accessed from the clinical workstation, automatically pre-populated with the available patient data and sent directly to DEMIS and the relevant health authorities with just one click. The filing of the dispatch confirmations is completely autonomous and saves the doctor around 30 minutes per patient.

We invested in Vertama because the solution not only addresses a major market challenge in the hospital sector, but also digitises manual micro-processes in many areas in a system-independent, simple, fast and secure way. This allows doctors, for example, to regain more time for their patients.

Frank Reinecke, Principal at HTGF

Hospitals can use Vertama’s services regardless of the clinical information system they use, can go live in just a few steps, and are already well prepared for future legal obligations in infection control. Further enhancements of the services for communication between hospitals and various authorities are already close to market.

With this set-up, founder and CEO Andre Sturm and his team were able to attract investors to support Vertama’s continued growth and sales expansion.

About Vertama
Vertama specialises in accelerating manual workflows by designing and implementing accessible, digital micro-processes in existing system environments. With its in-house developed platform for innovative web applications and a comprehensive toolkit of different modules, Vertama quickly implements flexible and scalable solutions.

About High-Tech Gründerfonds 
The seed investor High-Tech Gründerfonds (HTGF) finances technology start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF has approximately 1.4 billion euros under management. The team of experienced investment managers and start-up experts supports the young companies with know-how, entrepreneurial spirit and passion. The focus lies on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. More than 4.5 billion euros have been invested in the HTGF portfolio by external investors in more than 2,000 follow-up funding rounds to date. Furthermore, the fund has already successfully sold their shares in more than 170 companies.
The fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Media contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa